Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 3Recruiting 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 23Other hematologic neoplasm 7Sarcoma 4Other solid neoplasm 2CNS 2Myeloid 1Dermatologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Blast Crisis 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 9fludarabine 8Cytarabine 8Busulfan 8Azacitidine 8Whole-Body Irradiation 7Methotrexate 7Cyclosporine 6Tacrolimus 5Filgrastim 5Decitabine 5nilotinib 4Mycophenolic Acid 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Dasatinib 3Biopsy 3AP 1903 reagent 3venetoclax 2sabatolimab 2ruxolitinib 2merphos 2magrolimab 2ivosidenib 2decitabine and cedazuridine drug combination 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Vincristine × Myeloid × Clear all
NCT01670084 2015-10-30

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Mayo Clinic

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡